These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 23166310)

  • 21. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors?
    Anderson JL; Vanwoerkom RC; Horne BD; Bair TL; May HT; Lappé DL; Muhlestein JB
    Am Heart J; 2011 Aug; 162(2):331-339.e2. PubMed ID: 21835295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasma parathyroid hormone level and prevalent cardiovascular disease in CKD stages 3 and 4: an analysis from the Kidney Early Evaluation Program (KEEP).
    Bhuriya R; Li S; Chen SC; McCullough PA; Bakris GL
    Am J Kidney Dis; 2009 Apr; 53(4 Suppl 4):S3-10. PubMed ID: 19285609
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Control of parathyroid function in patients with a short history of hemodialysis.
    Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M
    Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adherence to mineral and bone disorder clinical practice guidelines in chronic kidney disease.
    Panawong W; Chaiyakum A; Pongskul C
    J Med Assoc Thai; 2011 Oct; 94(10):1175-83. PubMed ID: 22145501
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomized trial comparing pulse calcitriol and alfacalcidol for the treatment of secondary hyperparathyroidism in haemodialysis patients.
    Kiattisunthorn K; Wutyam K; Indranoi A; Vasuvattakul S
    Nephrology (Carlton); 2011 Mar; 16(3):277-84. PubMed ID: 21342321
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The need for better control of secondary hyperparathyroidism.
    Locatelli F
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V15-19. PubMed ID: 15284355
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients.
    Mazzaferro S; Pasquali M; Farcomeni A; Vestri AR; Filippini A; Romani AM; Barresi G; Pugliese F
    Nephrol Dial Transplant; 2008 Jul; 23(7):2319-23. PubMed ID: 18281320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective study on dialysis patients after total parathyroidectomy without autoimplant.
    Chan HW; Chu KH; Fung SK; Tang HL; Lee W; Cheuk A; Yim KF; Tong MK; Lee KC
    Nephrology (Carlton); 2010 Jun; 15(4):441-7. PubMed ID: 20609096
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cinacalcet treatment and serum FGF23 levels in haemodialysis patients with secondary hyperparathyroidism.
    Koizumi M; Komaba H; Nakanishi S; Fujimori A; Fukagawa M
    Nephrol Dial Transplant; 2012 Feb; 27(2):784-90. PubMed ID: 21730210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implementation of 'K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease' after the introduction of cinacalcet in a population of patients on chronic haemodialysis.
    Arenas MD; Alvarez-Ude F; Gil MT; Moledous A; Malek T; Nuñez C; Devesa R; Carretón MA; Soriano A
    Nephrol Dial Transplant; 2007 Jun; 22(6):1639-44. PubMed ID: 17277339
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism.
    Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA;
    Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis.
    Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA
    Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study.
    Fernández-Martín JL; Dusso A; Martínez-Camblor P; Dionisi MP; Floege J; Ketteler M; London G; Locatelli F; Górriz JL; Rutkowski B; Bos WJ; Tielemans C; Martin PY; Wüthrich RP; Pavlovic D; Benedik M; Rodríguez-Puyol D; Carrero JJ; Zoccali C; Cannata-Andía JB;
    Nephrol Dial Transplant; 2019 Apr; 34(4):673-681. PubMed ID: 29741651
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Co-trending of parathyroid hormone and phosphate in patients receiving hemodialysis.
    Block G; Do TP; Collins AJ; Cooper KC; Bradbury BD
    Clin Nephrol; 2016 Mar; 85(3):142-51. PubMed ID: 26784912
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Parathyroid and bone. Mineral and bone disorder and parathyroid function in chronic kidney disease].
    Yano S
    Clin Calcium; 2007 Dec; 17(12):1870-8. PubMed ID: 18057663
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Achievement of recommended treatment targets for bone and mineral metabolism in haemodialysis patients using paricalcitol: an observational study.
    Fernström A; Giæver J; Granroth B; Hylander B; Jensen G; Christensson A; Wikström B; Weiss L; Wrege U; Jacobson SH
    Scand J Urol Nephrol; 2011 Apr; 45(3):196-205. PubMed ID: 21366390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Emerging drugs for secondary hyperparathyroidism.
    Cozzolino M; Tomlinson J; Walsh L; Bellasi A
    Expert Opin Emerg Drugs; 2015 Jun; 20(2):197-208. PubMed ID: 25702624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of mineral and bone disorder in chronic kidney disease: quo vadis?
    Nakai K; Komaba H; Fukagawa M
    Ther Apher Dial; 2009 Oct; 13 Suppl 1():S2-6. PubMed ID: 19765254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Different effects of calcitriol and parathyroidectomy on the PTH-calcium curve in dialysis patients with severe hyperparathyroidism.
    Malberti F; Corradi B; Cosci P; Colecchia M; Leopardi O; Grossi L; Oldini C; Imbasciati E
    Nephrol Dial Transplant; 1996 Jan; 11(1):81-7. PubMed ID: 8649657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK
    Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.